Replimune Group (NASDAQ:REPL) Announces Earnings Results, Misses Estimates By $0.09 EPS

Replimune Group (NASDAQ:REPL) issued its quarterly earnings data on Wednesday. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09), Zacks reports.

Replimune Group Stock Up 0.0 %

Replimune Group stock traded up $0.00 during mid-day trading on Friday, reaching $14.29. The stock had a trading volume of 72,987 shares, compared to its average volume of 753,477. The company has a market capitalization of $978.00 million, a price-to-earnings ratio of -4.69 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a 50-day moving average price of $12.49 and a two-hundred day moving average price of $11.67.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

REPL has been the subject of a number of research analyst reports. HC Wainwright raised their target price on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday. Jefferies Financial Group raised their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets upped their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $19.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.